Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback